Information on Withdrawn Rights issue Q1 2024

1. Investors who have submitted subscription commitments will receive back the subscription amount excluding expenses to e.g. the bank or financial intermediaries.
2. Purchasers of subscription rights will not be compensated for the purchase of subscription rights and they will only receive a subscription amount back ex. Expenses, if they have submitted a subscription commitment.

For investors who have traded temporary shares, the subscription amounts less expenses will go to the last registered owner of the temporary share.

You can participate in the rights issue by exercising your subscription rights through your custodian bank or broker. Subscription rights are traded on Spotlight Stock market and additional rights can thus be acquired over market.

The general public and existing shareholders can subscribe for any Remaining Shares that have not been subscribed in the issue. You can subscribe by completing a subscription form, which is available on Curasight’s website (www.curasight.com), Redeye’s website (www.redeye.se) and Nordic Issuing’s website (www.nordic-issuing.se). The subscription form needs to be completed and submitted to the account holder’s own bank according to their instructions.

Participating in the rights issue supports Curasight by providing the company with new funds, aiding Curasight’s accelerated strategy and ongoing clinical trials. In contrast, acquiring shares on the stock market lacks this direct benefit, as the funds exchanged occur solely between investors without benefiting the company itself.

Therefore, by subscribing to the Rights Issue, you actively support Curasight and contribute to the company’s mission of pioneering theranostic approaches to diagnose and treat certain types of cancer with the aim of providing clinicians and patients with innovative solutions.

Yes, you can purchase more shares than your current shareholding allows for, by acquiring additional subscription rights (if available) in the market during the rights trading period.

The general public and existing shareholders can subscribe for any Remaining Shares that have not been subscribed in the issue. Subscription shall be made via the completion of a subscription form, which is available on Curisight’s website (www.curasight.com), Redeye’s website (www.redeye.se) and Nordic Issuing’s website (www.nordic-issuing.se). The subscription form must be completed and submitted to the account holder’s own bank according to their instructions.

You can subscribe for fewer shares than your current shareholding allows for by exercising only a portion of your subscription rights during the subscription period.

If you do not want to participate in the Rights Issue, you can choose not to exercise your subscription rights during the subscription period. Alternatively, you may also sell your subscription rights on the market during the rights trading period.

No, once you have exercised your subscription rights and placed your order for new shares, it cannot be changed or annulled. The subscription is binding.

Yes, the general public can participate in the rights issue by subscribing for any remaining shares after existing shareholders have exercised their subscription rights, subject to availability. Furthermore, subscription rights are traded on Spotlight stock market, meaning that subscription rights can be acquired over market.

There may be fees charged by your custodian bank or broker for participating in the Rights Issue, and you would also need to pay the subscription price for the new shares you are acquiring.

The tax implications of participating in the Rights Issue would depend on your individual tax jurisdiction and circumstances. It's advisable to consult with a tax advisor to understand any potential tax implications